Sun Pharmaceutical Industries Limited (Sun Pharma) is among India’s leading pharmaceutical companies. With its current share price at ₹1,782, the company is a prominent player in the healthcare sector, both domestically and globally. Let’s dive into Sun Pharma’s future share price targets and growth potential.
About Sun Pharma
Sun Pharma is one of the largest specialty generic pharmaceutical companies globally. Known for its robust portfolio of generics, specialty drugs, and over-the-counter products, it caters to over 100 markets worldwide.
Company Details
- Founded: 1983
- Headquarters: Mumbai, India
- Sector: Pharmaceuticals
- Global Presence: Over 100 countries
- Competitors: Dr. Reddy’s, Cipla, Lupin
Promoter Details
| Promoter Name | Holding (%) |
|---|---|
| Dilip Shanghvi & Family | 54.48 |
| Public & Institutional Investors | 45.52 |
Sun Pharma Share Price Target 2024
Growth Drivers:
- Expansion in specialty drugs and generics.
- Focus on innovation and R&D.
- Minimum Target: ₹1,850
- Maximum Target: ₹1,950
Sun Pharma Share Price Target 2025
Key Catalysts:
- Strong global growth in specialty products.
- Rising demand for chronic and lifestyle disease treatments.
- Minimum Target: ₹2,000
- Maximum Target: ₹2,150
Sun Pharma Share Price Target 2026 to 2030
| Year | Minimum Target (₹) | Maximum Target (₹) |
|---|---|---|
| 2026 | 2,200 | 2,350 |
| 2027 | 2,400 | 2,600 |
| 2028 | 2,650 | 2,850 |
| 2029 | 2,900 | 3,150 |
| 2030 | 3,200 | 3,500 |
Sun Pharma Share Price Target 2035
With advancements in biotechnology and personalized medicine, Sun Pharma is poised for substantial growth by 2035.
- Minimum Target: ₹4,500
- Maximum Target: ₹5,000
Sun Pharma Share Price Target 2040
By 2040, Sun Pharma’s investments in innovation, market diversification, and R&D are expected to yield impressive returns.
- Minimum Target: ₹6,500
- Maximum Target: ₹7,500
Final Thoughts
Sun Pharma remains a strong contender for long-term investments due to its consistent innovation, robust global presence, and focus on high-demand healthcare segments.
Disclaimer: Always conduct thorough research or consult a financial advisor before investing in stocks. For more insights, visit moneyphobia.in!
